A. Inversions, extra chromosomes, and frameshift deletions B. Germline, somatic, and missense mutations C. Monosomy, trisomy, and point mutations D. Chromosomal rearrangement, long arm additions, and amplifications E. Unsure

A. Begin standard treatment with therapy prior to receipt of molecular testing results and consider changing if a target is identified B. Assume the most common and prevalent molecular alteration is present and begin an agent empirically C. Wait until all tissue and molecular testing results are finalized prior to selection and initiation of any systemic therapy D. Biopsy a second lesion to ensure uniformity of tissue acquisition and molecular testing platform in case of poor sensitivity E. Unsure

A. Improved overall survival rates B. Reduced costs to patients and the healthcare system C. Reduced frequency and severity of grade 3 and 4 adverse events D. A more straightforward path to combination approaches E. Unsure